Rinvoq ER 15 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DX25F6PMH
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $14,896
Award facts
- Contract value 100% obligated
- $14,896.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $14,896.28 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) on June 2, 2025, with completion scheduled for June 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as the comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills critical federal medical procurement needs through its extensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's demonstrated capability to meet federal requirements through open competition is evidenced by its consistent receipt of competitively awarded delivery orders from the Defense Logistics Agency, which support military and veteran healthcare systems. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, representing the type of specialty pharmaceutical medication typical of AmerisourceBergen's federal medical supply portfolio.
Quick answers
Who was awarded contract SPE2DX25F6PMH?
SPE2DX25F6PMH was awarded to Amerisourcebergen Drug Corp by Medical Supply Chain (Troop Support) on June 2, 2025.
How much is contract SPE2DX25F6PMH worth?
The government has obligated $14,896 on SPE2DX25F6PMH.
Is contract SPE2DX25F6PMH an order under another contract?
Yes. SPE2DX25F6PMH is a delivery order under SPE2DX15D1053, an indefinite delivery contract.
Was contract SPE2DX25F6PMH competed?
The extent of competition for SPE2DX25F6PMH was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award